AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21050302 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mammography screening
Number of subjects: 0
Study 17638548 — intervention group
Group type: EXPERIMENTAL
Intervention: IVU before SWL (n = 100)
Number of subjects: 200
Study 17638548 — intervention group
Group type: COMPARATOR
Intervention: SWL without IVU (n = 100)
Number of subjects: 200
Study 16412928 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% instilled hourly for 10 hours
Number of subjects: 0
Study 16412928 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% instilled hourly for 10 hours
Number of subjects: 0
Study 16412928 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% instilled 4 times a day for 7 days
Number of subjects: 0
Study 16412928 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% instilled 4 times a day for 7 days
Number of subjects: 0
Study 16412928 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% and Moxifloxacin 0.5%
Number of subjects: 0
Study 12441586 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken Soup for the Soul at Work Employee Groups intervention, consisting of nine weekly meetings.
Number of subjects: 0
Study 12441586 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group, no specific intervention mentioned.
Number of subjects: 0
Study 10465313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian interim analysis methods for monitoring randomized controlled Phase II trials
Number of subjects: 0
Study 10465313 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 7570433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 5 mg and ipratropium bromide 500 micrograms (4 times a day)
Number of subjects: 70
Study 7570433 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol 5 mg alone (4 times a day)
Number of subjects: 70
Study 2405936 — intervention group
Group type: EXPERIMENTAL
Intervention: Aust pyloroplasty (group 2)
Number of subjects: 40
Study 2405936 — intervention group
Group type: COMPARATOR
Intervention: Control group (pylorus left intact, group 1)
Number of subjects: 40
Study 2405936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (gastric emptying test)
Number of subjects: 40
Study 519476 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 30 mg/kg
Number of subjects: 0
Study 519476 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 0
Study 519476 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel split regimen (two doses of 20 mg/kg given four hours apart)
Number of subjects: 0
Study 519476 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (all regimens)
Number of subjects: 0
Study 30594109 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight suppression (difference between highest past and current weight)
Number of subjects: 294
Study 30594109 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline body fat (covariate)
Number of subjects: 294
Study 27853049 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly regimen (MR): 1.5 g iv methylprednisolone monthly for 3 months
Number of subjects: 40
Study 27853049 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen (WR): 0.5 g iv methylprednisolone weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks
Number of subjects: 40
Study 25597555 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired olfaction (defined as an olfactory score below the fifth percentile of normative data)
Number of subjects: 165
Study 25597555 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired olfaction
Number of subjects: 165
Study 23863351 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min, daily for five days a week, for three weeks)
Number of subjects: 32
Study 23863351 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 32
Study 23863351 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study 21807137 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (ibuprofen)
Number of subjects: 36
Study 21807137 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 36
Study 21807137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19743621 — intervention group
Group type: EXPERIMENTAL
Intervention: modified multidrug therapy (mMDT) including rifampicin, clofazimine, and dapsone for 1 year
Number of subjects: 794
Study 19743621 — intervention group
Group type: COMPARATOR
Intervention: Control group (137 patients observed)
Number of subjects: 794
Study 17082663 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly low-dose rituximab (20 mg/m2)
Number of subjects: 12
Study 17082663 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly low-dose rituximab (60 mg/m2)
Number of subjects: 12
Study 17082663 — intervention group
Group type: COMPARATOR
Intervention: Standard dose infusion of rituximab (375 mg/m2)
Number of subjects: 12
Study 15278031 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP group)
Number of subjects: 171
Study 15278031 — intervention group
Group type: COMPARATOR
Intervention: No omentoplasty (NO group)
Number of subjects: 171
Study 11402249 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO) 1.0 g á kg body mass(‐1)
Number of subjects: 10
Study 11402249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10
Study 11402249 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 10
Study 9424000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (3 g in 15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Number of subjects: 86
Study 9424000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Number of subjects: 86
Study 8098520 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% apraclonidine
Number of subjects: 109
Study 8098520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 3030392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen-CPA therapy
Number of subjects: 76
Study 3030392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 31982885 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (treatment group)
Number of subjects: 89
Study 31982885 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 30561169 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood minimal residual disease (PB-MRD) assessment at day 8
Number of subjects: 288
Study 30561169 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-MRD assessment at days 33 and 52
Number of subjects: 288
Study 30561169 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic assessment of PB-MRD
Number of subjects: 288
Study 30561169 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 15 bone marrow MRD (BM-MRD)
Number of subjects: 288
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage-to-care within 365 days of testing HIV-positive
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (≤30 years) vs >40 years
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 31-40 years vs >40 years
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being South African
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban district
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Being employed
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondisclosure of HIV status
Number of subjects: 2398
Study 28961678 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CD4 counts
Number of subjects: 2398
Study 25542604 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment
Number of subjects: 2
Study 25542604 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 2
Study 23399552 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 8067
Study 23399552 — intervention group
Group type: COMPARATOR
Intervention: Nonselective NSAIDs (nsNSAIDs)
Number of subjects: 8067
Study 21729462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 343
Study 21729462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A + Zn supplementation
Number of subjects: 343
Study 21729462 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn supplementation
Number of subjects: 343
Study 21729462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 21729462 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall growth faltering
Number of subjects: 343
Study 21729462 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation
Number of subjects: 343
Study 18455961 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory low-frequency rTMS over contralesional motor cortex (20 min, 1200 stimuli) once per day for 8 days
Number of subjects: 10
Study 18455961 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 18455961 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory low-frequency rTMS over contralesional motor cortex
Number of subjects: 10
Study 16522992 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/d
Number of subjects: 175
Study 16522992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 16522992 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 8 mg/d (if needed)
Number of subjects: 175
Study 16522992 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin GITS and Placebo
Number of subjects: 175
Study 15264442 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants imagining they had won a lottery and responding to a 34-item questionnaire
Number of subjects: 80
Study 15264442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender of participants
Number of subjects: 80
Study 11217682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine against tetanus, diphtheria and polio (Td-IPV)
Number of subjects: 500
Study 11217682 — intervention group
Group type: COMPARATOR
Intervention: Separate Td and IPV injections
Number of subjects: 500
Study 9387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperthyroid therapy
Number of subjects: 14
Study 9387055 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients in remission)
Number of subjects: 14
Study 8329293 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide treatment (200 mg twice daily)
Number of subjects: 70
Study 3791629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg every 12 hr for one week)
Number of subjects: 10
Study 3791629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30348097 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training program delivered in non-medical settings for five days
Number of subjects: 0
Study 30348097 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training program
Number of subjects: 0
Study 30348097 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 27460004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MYmind protocol) consisting of 8 weekly 1.5-hour sessions
Number of subjects: 120
Study 27460004 — intervention group
Group type: COMPARATOR
Intervention: Short-acting methylphenidate administered individually
Number of subjects: 120
Study 24881730 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg once daily)
Number of subjects: 1717
Study 23342564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative potential water (OPW)
Number of subjects: 40
Study 23342564 — intervention group
Group type: COMPARATOR
Intervention: 1% NaOCl (control)
Number of subjects: 40
Study 23342564 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OPW and NaOCl
Number of subjects: 40
Study 21164394 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 18795522 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.0 mm (Group A)
Number of subjects: 40
Study 18795522 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.4 mm (Group B)
Number of subjects: 40
Study 18795522 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.6 mm (Group C)
Number of subjects: 40
Study 18795522 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal access diameter of 1.8 mm (Group D)
Number of subjects: 40
Study 15920062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg daily for 8 weeks
Number of subjects: 46
Study 15920062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12704548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy performed concurrently with surgical intervention (group A)
Number of subjects: 198
Study 12704548 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy performed 28 days after surgical intervention (group B)
Number of subjects: 198
Study 11459384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 100
Study 11459384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy (NT)
Number of subjects: 100
Study 11459384 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive and nutritional therapy (CNT)
Number of subjects: 100
Study 11459384 — intervention group
Group type: COMPARATOR
Intervention: Support group (SG)
Number of subjects: 100
Study 9220308 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (60-120 mg/d)
Number of subjects: 36
Study 9220308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7970085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin retard
Number of subjects: 53
Study 7970085 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 53
Study 3600277 — intervention group
Group type: EXPERIMENTAL
Intervention: antithyroid drug methimazole + thyroxine
Number of subjects: 30
Study 3600277 — intervention group
Group type: COMPARATOR
Intervention: beta 1‐selective adrenoceptor blocking agent metoprolol
Number of subjects: 30
Study 28505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based aerobic exercise (AE)
Number of subjects: 57
Study 28505303 — intervention group
Group type: COMPARATOR
Intervention: Health-education control (HEC)
Number of subjects: 57
Study 26414008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined education with feedback (intervention)
Number of subjects: 3
Study 24411542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-rib harvest intercostal block
Number of subjects: 120
Study 24411542 — intervention group
Group type: COMPARATOR
Intervention: Post-rib harvest intercostal block
Number of subjects: 120
Study 22776874 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 10 min aerobic exercise
Number of subjects: 11
Study 22776874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 30 min aerobic exercise
Number of subjects: 11
Study 22776874 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 20701025 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (single oral dose)
Number of subjects: 28
Study 20701025 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with simultaneous administration of methimazole (in 12 patients)
Number of subjects: 28
Study 20701025 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment (in 12 patients who were re-assessed after becoming euthyroid)
Number of subjects: 28
Study 20701025 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy persons)
Number of subjects: 28
Study 18237823 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 1 g b.i.d. for 3 months
Number of subjects: 32
Study 18237823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in pre-enrollment therapy)
Number of subjects: 32
Study 15964747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 103
Study 15964747 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 103
Study 15964747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 103
Study 12615677 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 107
Study 12615677 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 107
Study 12615677 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 107
Study 12615677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 107
Study 12615677 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, Atorvastatin, Cerivastatin
Number of subjects: 107
Study 11276623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing instructional program
Number of subjects: 122
Study 11276623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study 8869414 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium, alkaline drinking water
Number of subjects: 21
Study 8869414 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium drinking water
Number of subjects: 21
Study 8869414 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium, protein-controlled diet
Number of subjects: 21
Study 1505561 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 6 mg
Number of subjects: 20
Study 1505561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31608833 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated guidelines
Number of subjects: 162
Study 31608833 — intervention group
Group type: EXPERIMENTAL
Intervention: Segregated guidelines
Number of subjects: 162
Study 31608833 — intervention group
Group type: COMPARATOR
Intervention: Control guidelines
Number of subjects: 162
Study 27590465 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage therapy
Number of subjects: 18
Study 26866774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low interitem distance (IID; consistency tendency likely)
Number of subjects: 341
Study 26866774 — intervention group
Group type: COMPARATOR
Intervention: High interitem distance (IID; consistency tendency suppressed)
Number of subjects: 341
Study 24907640 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais method (n=30), one 2-hour session per week for 12 weeks
Number of subjects: 61
Study 24907640 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (n=31)
Number of subjects: 61
Study 22074297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% mannanoligosaccharides (MOS)
Number of subjects: 16
Study 22074297 — intervention group
Group type: COMPARATOR
Intervention: Control diet (without MOS)
Number of subjects: 16
Study 20486905 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (Evr) monotherapy after 10 days of cyclosporine (CsA)
Number of subjects: 78
Study 20486905 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) with/without mycophenolate mofetil
Number of subjects: 78
Study 20486905 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (Evr) monotherapy
Number of subjects: 78
Study 20486905 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 78
Study 17464918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (0.2%) administered for 30 seconds before dental manipulation
Number of subjects: 106
Study 17464918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine mouthwash)
Number of subjects: 106
Study 16328570 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal proportional hazards model
Number of subjects: 0
Study 16328570 — intervention group
Group type: COMPARATOR
Intervention: Traditional proportional hazards model
Number of subjects: 0
Study 12386035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control of blood glucose concentration and blood pressure
Number of subjects: 0
Study 9797106 — intervention group
Group type: EXPERIMENTAL
Intervention: First FISH procedure
Number of subjects: 28
Study 9797106 — intervention group
Group type: EXPERIMENTAL
Intervention: Second FISH procedure
Number of subjects: 28
Study 9797106 — intervention group
Group type: EXPERIMENTAL
Intervention: Third FISH procedure
Number of subjects: 28
Study 9797106 — intervention group
Group type: EXPERIMENTAL
Intervention: First FISH procedure (Group 2)
Number of subjects: 28
Study 9797106 — intervention group
Group type: EXPERIMENTAL
Intervention: Second FISH procedure (Group 2)
Number of subjects: 28
Study 9797106 — intervention group
Group type: EXPERIMENTAL
Intervention: Third FISH procedure (Group 2)
Number of subjects: 28
Study 7619663 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg day‐1 for 4 days and 10 mg on day 5)
Number of subjects: 0
Study 7619663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone (15 mg day‐1 for 4 days and 5 mg on day 5)
Number of subjects: 0
Study 7619663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7619663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg intravenous administration)
Number of subjects: 0
Study 2229614 — intervention group
Group type: EXPERIMENTAL
Intervention: High-copper spherical-particle dental amalgam with 0.5% Pd
Number of subjects: 193
Study 2229614 — intervention group
Group type: COMPARATOR
Intervention: High-copper spherical-particle dental amalgam without Pd
Number of subjects: 193
Study 646499 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a Penrose drain
Number of subjects: 334
Study 646499 — intervention group
Group type: COMPARATOR
Intervention: No drain used
Number of subjects: 334
Study 646499 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain used
Number of subjects: 334